Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid for Bone Metastases in Advanced Cancer/Myeloma
NCT00330759Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2006
- Primary completion
- Apr 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in bone metastasis, multiple myeloma (MM), sponsored by Amgen. Started Jun 2006; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasismultiple myeloma (MM)
Beyond the preview
Go deeper on NCT00330759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330759.